Collin Nicolas, de Radiguès Xavier
World Health Organization, 1211 Geneva 27, Switzerland.
Vaccine. 2009 Aug 20;27(38):5184-6. doi: 10.1016/j.vaccine.2009.06.034. Epub 2009 Jun 27.
The first influenza pandemic of the 21st century, due to a new strain of A(H1N1) virus, was declared on 11 June 2009 by the Director-General of the World Health Organization. Fortunately, the international community, including influenza vaccine manufacturers, has been increasing its preparedness for such an event, triggered by the need to stem the spread of the highly pathogenic avian influenza A(H5N1) virus over recent years. Today, the development of a pandemic influenza vaccine in the fastest possible time is a global priority. However, two major issues need to be taken into consideration: how long will it take to produce sufficient pandemic vaccine doses to immunize the global population at risk, including poor populations that have no resources to purchase the vaccine; and how will pandemic vaccine production affect availability of trivalent vaccine for the forthcoming 2009-2010 influenza season. To address these questions, WHO carried out a survey in May 2009 among influenza vaccine manufacturers on their planned seasonal and pandemic production with a view to developing recommendations on the distribution and use of pandemic influenza vaccine.
2009年6月11日,世界卫生组织总干事宣布,由一种新型A(H1N1)病毒株引发的21世纪首次流感大流行爆发。幸运的是,包括流感疫苗制造商在内的国际社会,由于近年来遏制高致病性甲型禽流感A(H5N1)病毒传播的需要,一直在加强对此类事件的防范。如今,尽快研发大流行性流感疫苗已成为全球优先事项。然而,有两个主要问题需要考虑:生产足够剂量的大流行疫苗以免疫全球高危人群,包括没有资源购买疫苗的贫困人口,需要多长时间;大流行疫苗的生产将如何影响2009-2010年即将到来的流感季节三价疫苗的供应。为解决这些问题,世卫组织于2009年5月对流感疫苗制造商进行了一项调查,了解他们计划的季节性和大流行疫苗生产情况,以便就大流行性流感疫苗的分发和使用制定建议。